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Abstract
Background: Tumor resistance to the selective estrogen receptor modulator tamoxifen remains a serious clinical
problem especially in patients with tumors that also overexpress HER2. We have recently demonstrated that the
clinically important isoform of HER2, HERΔ16, promotes therapeutically refractory breast cancer including resistance
to endocrine therapy. Likewise additional breast tumor cell models of tamoxifen resistance have been developed
that do not involve HER2 overexpression. However, a unifying molecular mechanism of tamoxifen resistance has
remained elusive.
Results: Here we analyzed multiple cell models of tamoxifen resistance derived from MCF-7 cells to examine the
influence of microRNAs (miRNAs) on tamoxifen resistance. We compared miRNA expression profiles of tamoxifen
sensitive MCF-7 cells and tamoxifen resistant MCF-7/HER2Δ16 cells. We observed significant and dramatic
downregulation of miR-342 in the MCF-7/HER2Δ16 cell line as well as the HER2 negative but tamoxifen resistant
MCF-7 variants TAMR1 and LCC2. Restoring miR-342 expression in the MCF-7/HER2Δ16 and TAMR1 cell lines
sensitized these cells to tamoxifen-induced apoptosis with a dramatic reduction in cell growth. Expression of miR-
342 was also reduced in a panel of tamoxifen refractory human breast tumors, underscoring the potential clinical
importance of miR-342 downregulation. Towards the goal of identifying direct and indirect targets of miR-342 we
restored miR-342 expression in MCF-7/HER2Δ16 cells and analyzed changes in global gene expression by
microarray. The impact of miR-342 on gene expression in MCF-7/HER2Δ16 cells was not limited to miR-342 in silica
predicted targets. Ingenuity Pathways Analysis of the dataset revealed a significant influence of miR-342 on
multiple tumor cell cycle regulators.
Conclusions: Our findings suggest that miR-342 regulates tamoxifen response in breast tumor cell lines and our
clinical data indicates a trend towards reduced miR-342 expression and tamoxifen resistance. In addition, our
results suggest that miR-342 regulates expression of genes involved in tamoxifen mediated tumor cell apoptosis
and cell cycle progression. Restoring miR-342 expression may represent a novel therapeutic approach to sensitizing
and suppressing the growth of tamoxifen refractory breast tumors.
Background
Nearly, 70% of breast cancer patients develop tumors
expressing the estrogen receptor (ERa) and are candidates
for endocrine therapy. The selective ERa modulator
tamoxifen, is the most commonly prescribed endocrine
therapy, but 30-40% of patients fail adjuvant tamoxifen
therapy and nearly all patients with metastatic disease
develop tamoxifen resistance [1]. Unfortunately, de novo
and acquired tumor resistance to tamoxifen therapy
remains a poorly understood and serious clinical problem.
Multiple causal events have been associated with anti-
estrogen resistance including loss of ERa expression [2],
selection of ERa mutants [3,4], and cross-talk between the
type I receptor tyrosine kinase family resulting in ligand-
independent activation of the ERa [5]. Several clinical
studies implicate the HER2 receptor tyrosine kinase as a
significant risk for tamoxifen failure. Approximately half of
the ERa positive tumors also express HER2 and over 70%
of these patients may exhibit de novo tamoxifen resistance
[6,7]. A large percentage of HER2/ERa positive tumors
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grow when patients are estrogen depleted [6].
MicroRNAs (miRNAs) are short (~22 bp), single-
stranded, non-coding RNAs that suppress gene expres-
sion by binding the 3’ UTR of target gene mRNAs.
They are thought to regulate up to one-third of the
human genome by targeting mRNAs for cleavage or
translational repression and miRNAs have recently been
identified as key players in cellular processes including
self-renewal, differentiation, growth and apoptosis, all of
which are deregulated in carcinogenesis. Several miR-
NAs have been shown to be differentially regulated in
breast cancer [8], and individual miRNAs that contri-
bute to tumorigenicity, invasion and metastasis have
been identified [9]. Recently, breast cancer prognostic
markers such as ERa and HER2 have been shown to be
regulated by miR-221/222 and miR-125, respectively
[10,11]. Importantly, miR-221/222 and the BCL-2 target-
ing miR-15a/16 have been shown to contribute to
tamoxifen resistance [11-13], implicating multiple miR-
NAs as important modulators of tamoxifen response. As
multiple mechanisms contribute to the acquisition of
tamoxifen resistance, it is likely that additional miRNA
regulators of endocrine response remain to be identified.
Recently we demonstrated that the oncogenic splice
isoform of HER2, HER2Δ16, is associated with meta-
static breast cancer and resistance to both trastuzumab
[14] and endocrine therapy [12,15]. Here we show that
deregulation of miR-342 contributes to tamoxifen resis-
tance in multiple models of tamoxifen resistance includ-
ing the HER2Δ16 overexpression model. Specifically, we
demonstrate that miR-342 is downregulated in tamoxi-
fen resistant breast tumor cell lines and tamoxifen
refractory human breast tumors. We propose that miR-
342 may emerge as an important marker for tamoxifen
response as well as a potential therapeutic.
Methods
Cell Lines
Human mammary carcinoma cell line MCF-7 was pur-
chased from the American Type Culture Collection
(Manassas, VA) and maintained in MEM supplemented
with 10% fetal bovine serum (FBS). The tamoxifen sensi-
tive MCF-7/HER2, MCF-7/pcDNA, and the tamoxifen-
resistant MCF-7/HER2Δ16 cell lines have been described
elsewhere [12,14,15]. The tamoxifen resistant MCF-7 var-
iants TAMR1 and LCC2 have been described previously
[16,17]. To generate the miR-342 expressing MCF-7/
HER2Δ16 cell line a 342 bp sequence containing the pre-
miR-342 sequence (GRCh37:14:100575892:100576190:1)
flanked by 100 bp upstream and downstream was pre-
pared as a minigene (Integrated DNA Technologies) and
subcloned into pCMV-puro-silencer (Ambion). The
same vector expressing a short scrambled sequence
(pCMV-puro-NC) was used as a control. Either pCMV-
miR-342 or pCMV-puro-NC were transfected into MCF-
7/HER2Δ16 cells using Fugene6 (Roche) and stable
clones were isolated.
miRNA Expression Profiling
Total RNA was isolated using miRVANA RNA Isolation
System (Ambion) and integrity of samples was confirmed
using a Bioanalyzer (Agilent). For miRNA profiling, biolo-
gical duplicates of cells cultured for 48 h in CS-FBS and
then treated with either 100 pM 17-b-estradiol alone or in
combination with 1.0 μM 4-hydroxytamoxifen (TAM)
were analyzed. Microarray assay was performed and
analyzed using a service provider (LC Sciences) using LC-
Science microRNA arrays miRHuman_11.0 which detects
miRNA transcripts listed in Sanger miRBase Release 11.0.
Northern Blot Analysis
Total RNA was isolated using miRVANA RNA isola-
tion Kit (Ambion) and 10 μg of RNA was separated by
electrophoresis on a 15% TBE/urea gel. RNA was
transferred to a Hybond NX membrane (Amersham/
Pharmacia), UV-crosslinked, and incubated in pre-
hybridization solution (6X SSC, 5X Denhart’ss o l u t i o n ,
0.2% SDS) for 1 h at 30°C. Membranes were then
hybridized (42°C for 16 h) with P
32-labeled DNA
probes corresponding to the complementary sequences
of the mature miR-342-3p. The blots were exposed for
48 to 72 hr and developed using Molecular Dynamics
Phosphoimaging.
Quantification of miR-342
Expression of miR-342 was quantitated by qRT-PCR
from total RNA exactly as described elsewhere [12].
Analysis of EVL mRNA by Quantitative Reverse
Transcription PCR
Expression of EVL was quantitated by qRT-PCR from




The patient population used for this study has been
described in detail elsewhere [18]. Formalin fixed paraf-
fin-embedded human primary breast tumors were
obtained from the Department of Pathology at the Uni-
versity of Colorado. Tumor samples were collected from
1978 to 1993 and patients underwent tamoxifen therapy.
Additional immunohistochemical, clinical, and patholo-
gical details of this cohort have been described else-
where [18-21].
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In situ hybridization (ISH) of 6 μm sections from
archived FFPE primary breast tumor specimens was per-
formed using standard techniques and double-DIG
Locked Nucleic Acid-modified DNA probe complemen-
tary to mature hsa-miR-342-3p or scrambled control
(Exiqon) according to the manufacturer’si n s t r u c t i o n s .
Each section was scored by comparing staining intensity
of stably expressing miR-342 MCF-7/HER2Δ16 cells
given a score of 3 and the MCF-7/HER2Δ16 cells with a
score of 0 to the staining of tumor cells present in each
section. Two independent observers were blind to
sample identification and independently scored each




Cell proliferation was measured as a function of metabo-
lism by 3-(4,5-dimethylthiazol-2-yl])-2,5-diphenyltetrazo-
lium bromide (MTT; Sigma, St. Louis, MO) assay exactly
as described elsewhere [22] with detailed modifications
[12]. Each sample was prepared in triplicate and the data
represent the mean and SE of at least three independent
experiments. Data was normalized to control-mock trea-
ted cells. Statistically significant differences between data
sets were determined using paired Student’s t test.
Apoptosis Assay
Cell death as a result of apoptosis was quantitated by
measuring mono- and oligonucleosomes release using
the Cell Death Detection ELISA PLUS Kit (Roche) fol-
lowing the manufacturer’s instructions.
Inhibition of miR-342
Each cell line plated at 3000 cells per well in a 96-well
tissue culture plate was cultured for 24 hrs in CS-
MEM and then transfected with 50 nM of miRIDIAN
miRNA inhibitor non-specific control 1 or miRIDIAN
miRNA inhibitor hsa-miR-342-3p (Dharmacon) using
Hyperfect Reagent (Qiagen) according to the manufac-
turer’s instructions. At one day post-transfection cells
were treated with 100 pM 17-b-estradiol alone or in
combination with 1.0 μM 4-hydroxytamoxifen and a
MTT growth assay was performed at five days post-
transfection or cell death as a result of apoptosis was
quantitated by measuring mono- and oligonucleosomes
release using the Cell Death Detection ELISA PLUS
Kit (Roche) following the manufacturer’s instructions.
Each sample was prepared in triplicate and the data
represent the mean and SE of at least three indepen-
dent experiments. Statistically significant differences
between data sets were determined using paired Stu-
dent’stt e s t .
Transient Expression of miR-342
Pre-miR miRNA Precursor Molecules (Ambion) for hsa-
miR-342-3p were transfected into cell lines at the indi-
cated concentrations using Hyperfect (Qiagen).
3’ UTR Reporter Assay
MCF-7 cells were plated at 5000 cells per well in a 48
well plate and transfected with 20 nM of hsa-miR-342-
3p (Ambion) or pre-miR negative control (Ambion)
using Hyperfect. The next day cells were transfected
with 1.0 μg of with pMir target firefly luciferase reporter
plasmid containing 3’ UTR sequences from BMP7 or
GEMIN4 (Origene) and 1.0 μg of renilla luciferase
expression plasmid pRL-SV40 with Fugene 6. At 48 hrs
post-transfection cells were analyzed using the Dual
Luciferase Assay Kit (Promega) according to the manu-
facturer’s instructions. Each sample was prepared in
d u p l i c a t ea n dt h ee n t i r ee x p eriment was repeated three
times.
Microarray Gene Expression Analysis
Total RNA from biological triplicates of MCF-7/
HER2Δ16-miR-342 and MCF-7/HER2Δ16-puro-NC was
labeled and hybridized to Affymetrix GeneChip Human
Exon 1.0 ST Array and data was analyzed using Gene-
Spring GX 9.0 (Agilent) software at the University of
Colorado Denver DNA Microarray Core Facility. Mole-
cular pathway and connectively maps of the dataset was
performed using Ingenuity Pathway Analysis software.
Results
miR-342 Expression is Suppressed in Tamoxifen Resistant
Breast Tumor Cells
We have recently shown that ectopic expression of
HER2Δ16, but not wild-type HER2 promotes tamoxifen
resistance and estrogen independence of ERa positive
MCF-7 cells in part through modulation of miR-15a/16
[12,15]. To identify additional miRNAs that influence
tamoxifen resistance we compared global miRNA
expression profiles of tamoxifen sensitive MCF-7/
pcDNA cells to tamoxifen resistant MCF-7/HER2Δ16
cells after treatment with 100 pM of 17-b-estradiol (E2)
alone or in combination with 1.0 μM 4-hydroxytamoxi-
fen (TAM). We first examined the impact of TAM on
miRNA expression in the two cell lines. We reasoned
that miRNAs associated with acquired TAM resistance
may be altered during TAM treatment. However no
miRNAs were significantly (p < 0.05) altered during
TAM treatment of MCF-7/pcDNA cells and only
expression of miR-125a was significantly (p <0 . 0 5 ) ,
albeit modestly (1.2 fold increase), altered during TAM
treatment of MCF-7/HER2Δ16 cells. Results from this
one set of cell lines suggest that TAM treatment fails to
significantly alter miRNA expression.
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lators of TAM response by comparing miRNA expression
profiles between MCF-7/pcDNA and MCF-7/HER2Δ16
cells while both cell lines are undergoing acute tamoxifen
treatment. Using this criteria we identified five significantly
(p < 0.05) altered miRNAs (Table 1). We focused follow-
up analysis on miR-342-3p (miR-342) which was the most
dramatically altered miRNA in the tamoxifen resistant
MCF-7/HER2Δ16 cells and miR-342 has recently been
shown to be associated with ERa(+) and HER2 (+) breast
tumors [23]. We first determined if loss of miR-342 was a
common feature of tamoxifen resistance by comparing
miR-342 expression by northern blot in multiple tamoxi-
fen sensitive and resistant MCF-7 variants. Interestingly,
the two tamoxifen sensitive MCF-7/pcDNA and MCF-7/
HER2 cell lines [12,15] expressed high levels of miR-342
whereas the tamoxifen resistant MCF-7/HER2Δ16 [12,15],
TAMR1 [17], and LCC2 [16] cell lines all exhibited drama-
tically suppressed levels of miR-342 (Figure 1A). Consis-
tent with these results, qRT-PCR analyses showed that
miR-342 is suppressed in the tamoxifen resistant MCF-7/
HER2Δ16 and TAMR1 cell lines when compared to
tamoxifen sensitive MCF-7/pcDNA cells (Figure 1B). With
the exception of the tamoxifen sensitive MCF-7/HER2
cells, treatment with E2 alone or in combination
with TAM did not significantly alter miR-342 expression
(Figure 1B). Importantly, expression of miR-342-5p was
between 10-80 fold lower than miR-342-3p and in many
cases miR-342-5p expression was at the limits of qRT-
PCR sensitivity (Additional File 1).
Because intronic miRNA expression is commonly
coordinated with expression of the miRNA host-gene
we also examined expression of the miR-342 host-gene
Ena/Vasp-like (EVL) in the tamoxifen sensitive and
resistant cell lines. In each cell line we observed a con-
cordance between the levels of EVL expression and
miR-342 expression (Figure 1C) suggesting that miR-
342 expression is directly coupled to expression of EVL.
Similar coordinate expression between EVL and miR-
342 has been reported in colorectal cancer [24]. In
breast cancer independent studies have shown that simi-
lar to EVL, expression of miR-342 is associated with
ERa(+) breast tumors http://www.oncomine.org
[23,25-27] further supporting co-expression of miR-342
with EVL in ERa(+) tumors.
miR-342 Expression is Suppressed in Primary Breast
Tumors Associated with Tamoxifen Failure
To determine if miR-342 downregulation was associated
with clinical tamoxifen failure, we used DIG-labeled
LNA modified miRNA probes to detect miR-342 in pri-
mary human breast tumors by ISH and independently
scored each tumor on a scale of 0-3 with 3 being the
most intense miR-342 staining (Additional File 2 and
Figure 2A, B). We examined 16 primary breast tumors
ER(+) from patients who underwent tamoxifen treat-
ment, 6 developed recurrences and metastasis during
tamoxifen treatment (non-responders), and 10 had non-
recurrent disease (responders). Although we failed to
obtain significance due to the small number of tumor
samples, we did find that responders had nearly two-
fold the levels of miR-342 expression when compared to
tumors from patients that failed tamoxifen therapy
(1.5 +/- 0.3 vs. 0.8 +/- 0.4)(Figure 2C).
Suppression of miR-342 Expression Promotes Tamoxifen
Resistance
To determine if modulation of miR-342 expression
impacts tamoxifen response we first suppressed miR-
342 expression in the tamoxifen sensitive MCF-7/
pcDNA and MCF-7/HER2 cell lines. Consistent with
our previously published results [12] treatment of MCF-
7/pcDNA and MCF-7/HER2 cells with 1.0 μMo f
tamoxifen resulted in growth suppression with an
increase in cellular apoptosis (Figure 3). Transient trans-
fection of each cell line with a miR-342 inhibitor pro-
moted partial but significant tamoxifen resistance (p <
0.01) with a significant decrease in tamoxifen induced
apoptosis (p < 0.005)(Figure 3). These results suggest
that expression of miR-342 sensitizes breast tumor cells
to tamoxifen treatment and tamoxifen resistance can be
acquired through suppression of miR-342.
Table 1 MicroRNAs Significantly Altered in Tamoxifen Treated MCF-7/pcDNA vs. MCF-7/HER2Δ16 Cells
miRNA MCF-7/pcDNA MCF-7/HER2Δ16 Fold Change E+TAM HER2Δ16/pcDNA p
E E+TAM E E+TAM
miR-1308 459 514 2434 1772 3.45 0.033
miR-125a-5p 5090 6432 5909 7179 1.12 0.034
miR-23a 7798 7427 6473 5191 -1.43 0.013
miR-1180 815 797 189 188 -4.24 0.036
miR-342-3p 1960 1386 166 166 -8.35 0.031
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Tumor Cells to Tamoxifen
To determine if miR-342 expression sensitizes breast
tumor cells to tamoxifen therapy, we reintroduced miR-
342 expression into the tamoxifen resistant MCF-7/
HER2Δ16 and TAMR1 cell lines. Restoration of miR-
342 expression in tamoxifen-resistant MCF-7/HER2Δ16
and TAMR1 cells sensitized both cell lines to tamoxifen
treatment with a significant reduction in cell growth
(Figure 4A) and significant increase in tamoxifen-
induced apoptosis (Figure 4B). Similar results were
obtained when MCF-7/HER2Δ16 cells were stained with
DAPI and Propidium Iodine (PI) 48 hr after tamoxifen
treatment. A dramatic increase in the number of PI
positive (dead cells) was observed in response to tamoxi-
fen treatment but only in cells where miR-342 expres-
sion was restored (Figure 4C). Taken together these
results implicate miR-342 expression as an important
mediator of tamoxifen induced apoptosis in breast
tumor cells.
miR-342 Regulates Genes Associated with Tumor Cell
Death and Cancer Pathways
Despite the efforts of several laboratories, the physiologi-
cal targets for miR-342 remain uncharacterized. Bioinfor-
matic analyses predict that miR-342 can target between
169 to 1069 different genes. In order to identify potential
direct and indirect targets of miR-342 we stably restored
miR-342 levels in the tamoxifen resistant MCF-7/
HER2Δ16 cell line and performed a gene expression ana-
lysis comparing vector control to miR-342 expressing
Figure 1 Expression of miR-342 is suppressed in tamoxifen
resistant breast tumor cells.( A )T o t a lR N Aw a si s o l a t e df r o m
tamoxifen-sensitive (MCF-7/HER2, MCF-7/pcDNA) and tamoxifen-
resistant (MCF-7/HER2Δ16, TAMR1) cell lines cultured for 48 hr in 5% CS-
FBS MEM and treated for 24 hr with 100 pM 17-b-estradiol (E2) and 1
μM 4-hydroxytamoxifen (TAM). RNA was analyzed by Northern Blot
using DNA probes specific for miR-342-3p (miR-342) and the 5S RNA
loading control. (B,C) Total RNA was isolated from each cell line treated
with vehicle or E2 alone or in combination with TAM for 24 hr and (B)
miR-342 or (C) EVL expression was analyzed by qRT-PCR and normalized
to actin mRNA values. Levels are relative to vehicle-treated MCF-7/
pcDNA cells. Data represents the mean +/- SE of triplicate samples.
Figure 2 Expression of miR-342 is suppressed in primary
breast tumors associated with tamoxifen failure. (A,B)
Photomicrograph of primary breast tumors stained for miR-342
expression by ISH from patients that (A) responded or (B) failed
tamoxifen therapy. (C) Scatter plot of primary breast tumor miR-342
ISH scores (range 0-3 with 3 highest staining levels) from 10
responders and 6 non-responders during tamoxifen treatment.
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bly transfected with an expression vector containing the
hsa-miR-342-3p precursor sequence (miR-342), resulted
in an approximate 7-fold increase in miR-342 levels
when compared to the parental MCF-7/HER2Δ16 cell
line (Figure 4A) with undetectable levels of miR-342-5p
expression (Additional File 3). As predicted, restoration
of miR-342 expression sensitized MCF-7/HER2Δ16 cells
to tamoxifen (Figure 5B).
Although miRNAs primarily suppress gene translation,
target gene mRNA levels are often suppressed as well
[28]. As a global approach to identifying miR-342 target
genes we performed gene expression profiling of MCF-7/
HER2Δ16 stably transfected with miR-342 compared to
vector control cells on a HuGene 1.0 Affymetrix microar-
ray platform. Differentially regulated genes in miR-342-
expressing MCF-7/HER2Δ16 cells were defined as those
with at least 1.5-fold change (p < 0.05) compared to vec-
tor expressing cells (Figure 5C). Genes that also changed
in vector expressing compared to parental MCF-7/
HER2Δ16 cells were excluded. By these criteria miR-342
expressing MCF-7/HER2Δ16 cells showed differential
expression of 160 genes, 13 of which are bioinformati-
cally predicted to be direct targets of miR-342 (Table 2).
Interestingly, 7 of these 13 genes were upregulated in the
miR-342 expressing MCF-7/HER2Δ16 cells (Table 2).
The microarray data was validated by performing qRT-
PCR of three miR-342 predicted target genes (SEMAD,
BMP7, GEMIN4) and TXNIP (Figure 5D) which is not a
predicted miR-342 target gene but highly upregulated in
miR-342 expressing MCF-7/HER2Δ16 cells. Luciferase
expression from the 3’ UTR sequences of GEMIN4 and
BMP7 was suppressed when coexpressed with miR-342
by 40 and 50%, respectively, suggesting that these genes
are direct targets of miR-342 (Figure 5E).
To identify functional pathways potentially modulated
by miR-342 expression we performed an Ingenuity Path-
way Analysis (version 8.5)(IPA) of the miR-342 regu-
lated gene set. Consistent with a role for miR-342 in
tamoxifen induced apoptosis, the “Cell Death” biological
function and more specifically “Apoptosis of Breast Can-
cer Cells” was the biological function most significantly
(p <7×1 0
-6) enriched with miR-342 regulated genes.
When canonical cellular pathways were analyzed for
miR-342 regulated genes, IPA identified miR-342 genes
most significantly enriched in the “Mitotic Roles of
Polo-Like Kinase” pathway (p < 0.0001)(Figure 6A).
Most relevant to breast cancer is the suppression of
pathway member cyclin B1 in miR-342 expressing
MCF-7/HER2Δ16 cells. Cyclin B1 directly contributes to
breast tumor cell proliferation and therapeutic resistance
[29]. Furthermore, cyclin B1 expression is an indepen-
dent negative prognostic factor in the breast cancer
clinic [30]. The next breast cancer relevant pathway sig-
nificantly enriched with miR-342 regulated genes was
“Hereditary Breast Cancer Signaling” (p < 0.002) which
includes multiple genes with obvious connections to
breast cancer (Figure 6B). Thus, in addition to a role in
apoptosis, our results sugge s tt h a tm i R - 3 4 2m a ya l s o
influence multiple stages of the cell cycle through cyclin
B1 suppression, multiple BRCA1 activities, p53 cell cycle
checkpoint function, and PTEN tumor suppressor
Figure 3 Suppression of miR-342 promotes tamoxifen resistance. The tamoxifen sensitive MCF-7/pcDNA and MCF-7/HER2 cell lines cultured
for 48 hr in 5% CS-FBS MEM were transfected with anti-miR-342 or anti-miR negative control (NC) and the next day treated with 100 pM E2
alone or in combination with 1.0 μM TAM for five days. (A) MTT assay was used to quantitate cell growth and (B) apoptosis was quantitated
using a Cell Death Detection ELISA. Data is represented as mean +/- SE of three independent experiments relative E2 treated MCF-7/pcDNA
cells. Asterisks indicate samples with significant differences as determined by paired Student’s t test (A, p < 0.01; B, p < 0.005).
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rigenesis and tumor cell response to therapeutic
intervention.
Discussion
Endocrine resistance remains an important problem in
the breast cancer clinic. Currently there are only a few
useful tumor markers to guide management decisions
for women with ERa(+) breast tumors. Here we investi-
gated the potential role of miRNAs in the regulation of
tamoxifen response with the goal of identifying miRNAs
that can be used to predict patient outcome during
tamoxifen therapy. We found several miRNAs whose
expression was altered in tamoxifen resistant breast
tumor cells. We further demonstrate that miR-342-3p
(miR-342), an ERa associated miRNA [23], was dramati-
cally suppressed in multiple tamoxifen resistant breast
tumor cell lines and in primary breast tumors of
patients who failed tamoxifen therapy. Importantly, rein-
troduction of miR-342 sensitized refractory breast
tumor cells to tamoxifen therapy suggesting that miR-
342 is an important regulator of tamoxifen response.
Multiple studies have demonstrated that miRNAs are
involved in estradiol-dependent breast tumor cell prolif-
eration [31,32]. Accordingly, estradiol regulates expression
of many miRNAs [31,32] and an ERa associated miRNA
signature has been identified in human breast tumors [23].
In contrast, miRNAs appear to counteract estrogen-
dependent cell proliferation and their expression is upre-
gulated by anti-estrogen treatment of breast tumor cells
[32]. In this study, we profiled miRNA expression in
tamoxifen-sensitive and resistant breast tumor cell lines
and we identified several miRNAs differentially regulated
in tamoxifen-resistant MCF-7 cells expressing the
HER2Δ16 oncogenic isoform of HER2 [14]. In corrobora-
tion with recent findings that deregulation of miRNAs
contributes to the acquisition of anti-estrogen resistance
[11-13], we show that miR-342, which is suppressed in
tamoxifen resistant cells, is associated with increased
tamoxifen sensitivity of breast tumor cells. Enhanced
expression of miR-342 in tamoxifen sensitive breast tumor
cells has been reported previously, however, the functional
significance of deregulated miR-342 was not investigated
by this group [13]. MiR-1308 and miR-1180 were also
deregulated by greater than 2-fold in tamoxifen treated
MCF-7/HER2Δ16 cells. Studies are in progress to decipher
the contribution of these miRNAs to HER2Δ16 mediated
endocrine resistance.
It is common for miRNAs located within transcrip-
tional units to be co-expressed with their host gene.
Although in situ methods for the detection of miRNA
expression are not in clinical use, the fact that miR-342
expression is tightly correlated to its host gene EVL in
multiple tumor cell models [24,33] including our breast
Figure 4 Restored miR-342 expression sensitizes resistant cells
to tamoxifen. (A-C) Tamoxifen resistant cell lines were cultured for
24 hr in 5% CS-FBS MEM then transfected with transfection reagent
alone, 20 nM of scrambled precursor negative control (miR-NC), or
20 nM of miR-342-3p precursor (miR-342). At 24 hr post-transfection
cells were treated for 96 hr with 100 pM of E2 alone or in
combination with 1.0 μM TAM. (A) MTT assay was used to measure
proliferation as a function of metabolism, (B) apoptosis was assayed
by cell death ELISA, or (C) cells were stained with DAPI and
propidium iodide (PI). (A,B) Each experiment was repeated three
times and the data is represented as the mean +/- SE of each cell
line relative to the E2 treated sample. Asterisks indicates significant
changes (p < 0.001) relative to E2 treated samples.
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Page 7 of 12Figure 5 Stable miR-342 expression alters gene expression and sensitizes MCF-7/HER2Δ16 cells to tamoxifen. (A) Three independent
total RNA samples purified from MCF-7/HER2Δ16 (Parental), stable MCF-7/HER2Δ16 cell lines expressing pCMV-puro-NC (Vector) or pCMV-miR-342
(miR-342) cultured for 48 hr in CS-FBS MEM were analyzed for miR-342 expression by qRT-PCR. (B) Each indicated cell line was cultured for 24 hr
in 5% CS-FBS MEM and treated for 96 hr with 100 pM of E2 alone or in combination with 1.0 μMo r5μM TAM. Each MTT experiment was
repeated three times and the data is represented as the mean +/- SE relative to the E2 treated sample. Asterisks indicates significant changes
(p < 0.04). (C) Heat map of microarray expression analysis of genes significantly altered (p < 0.001) by at least 1.5 fold in stable miR-342
expressing MCF-7/HER2Δ16 cells. (D) Microarray validation by qRT-PCR of three suppressed miR-342 direct target genes (SEMAD, BMP7, GEMIN4)
and an upregulated indirect miR-342 target gene (TXNIP), normalized to b-actin, and expressed relative to parental MCF-7/HER2Δ16 cells.
Asterisks indicate significant differences (p < 0.05). (E) MiR-342 inhibition of GEMIN4 and BMP7 3’ UTRs. MCF-7 cells were transfected with 20 nM
of hsa-miR-342-3p (Ambion) or pre-miR negative control (Ambion) followed by pMir target firefly luciferase reporter plasmid containing 3’ UTR
sequences from BMP7 or GEMIN4 (Origene) and a renilla luciferase expression vector. At 48 hrs post-transfection cells were analyzed using the
Dual Luciferase Assay Kit (Promega) according to the manufacturer’s instructions. Each sample was prepared in duplicate and the entire
experiment was repeated three times. Data represents mean +/- SE percent inhibition of luciferase activity of miR-342 transfected cells relative to
pre-miR negative control.
Table 2 Target genes significantly modulated by miR-342 expression
Gene Symbol Gene Title Fold Change
NR4A2 nuclear receptor subfamily 4, group A, member 2 1.7
MAGED2 melanoma antigen family D, 2 1.7
LASP1 LIM and SH3 protein 1 1.7
UCP2 uncoupling protein 2 1.6
THSD4 thrombospondin, type I, domain containing 4 1.6
PRODH proline dehydrogenase (oxidase) 1 1.6
PIP4K2C phosphatidylinositol-5-phosphate 4-kinase, type II, gamma 1.6
MEIS1 meis homeobox 1 -1.7
BMP7 bone morphogenetic protein 7 -1.8
PRR6 proline rich 6 -1.8
GEMIN4 gem associated protein 4 -2.1
GJA1 gap junction protein, alpha 1 -2.2
SEMA3D semaphorin 3D -2.3
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Page 8 of 12Figure 6 Ingenuity Pathway Analysis (IPA) of miR-342 regulated genes. Pathways most significantly enriched with miR-342 regulated genes
included (A) Mitotic Roles of Polo-Like Kinase (p < 0.0001) and (B) Hereditary Breast Cancer Signaling (p < 0.002). Genes significantly upregulated
are indicated in red and significantly downregulated genes are indicated in green. Color intensity indicates extent of upregulation or
downregulation.
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Page 9 of 12tumor cell lines, provides a unique opportunity to use
EVL mRNA expression as a surrogate marker for miR-
342 expression in breast cancer patients. Mining of
archived microarray data revealed that EVL expression
is significantly associated with ERa( + )b r e a s tt u m o r s
[25-27] which is consistent with recent studies reporting
a strong correlation between ERa and miR-342 expres-
sion [23]. Significantly, ERa(+) breast tumors that fail
tamoxifen therapy with rapid recurrence within 3 years
have significantly lower EVL expression levels [34],
providing compelling support for the hypothesis that
miR-342 suppression promotes tamoxifen resistance. In
colorectal cancer cells EVL/miR-342 expression is sup-
pressed through hypermethylation of the EVL promoter
[24]. We are currently investigating a similar mechanism
of miR-342 suppression in tamoxifen resistant breast
tumor cells.
A direct gene target of miR-342 remains to be experi-
mentally confirmed and bioinformatics reveals over 1000
potential miR-342 targets. As an approach to the identifi-
cation of miR-342 targets we examined transcriptome
changes in miR-342 overexpressing cells by microarray
analysis. We observed significant alteration of 13 genes
predicted by bioinformatics to be miR-342 targets. Inter-
estingly, the majority of predicted target genes were up-
regulated by miR-342 expression. Although miRNAs
commonly suppress target gene mRNA levels, accumu-
lating evidence suggests that miRNAs can target genes
for up-regulation by at leastt w od i f f e r e n tm e c h a n i s m s
[35]. Although we could not identify an obvious associa-
tion between the direct targets of miR-342 and tumor
cell response to tamoxifen, Ingenuity Pathway Analysis of
the entire set of genes significantly altered by miR-342
revealed a highly significant association of miR-342 regu-
lated genes with cell apoptosis. This result is consistent
with our observation that ectopic miR-342 expression
sensitized tamoxifen resistant cells to tamoxifen-induced
apoptosis. Similarly, miR-342e x p r e s s i o ni nc o l o r e c t a l
cancer cells results in tumor cell apoptosis [24]. Never-
theless, activity of miR-342 appears to be functionally dif-
ferent in colorectal and breast tumor cells. Our results
indicate that miR-342 expression alone is not sufficient
to induce cell death, but miR-342 sensitizes cells to apop-
tosis associated with estrogen-deprivation and tamoxifen
exposure. In this context, the miR-342 indirect target
thioredoxin-interacting protein (TXNIP) is the most dra-
matically upregulated gene in response to miR-342
expression and could potentially mediate miR-342 action.
Accordingly, TXNIP expression is induced in tumor cells
by various stresses including serum starvation [36],
which mimics ERa inactivation in breast tumors, and
enhanced TXNIP expression has tumor-suppressor activ-
ity [36,37]. Similar to our findings that miR-342 sensitizes
breast tumor cells to tamoxifen, TXNIP sensitizes breast
tumor cells to paclitaxel [38]. Although these results are
compelling, TXNIP is an upregulated indirect target of
miR-342 and deciphering the interplay between miR-342
and TXNIP has proved difficult.
Although tamoxifen clearly induces breast tumor cell
apoptosis, cytostasis is considered the predominant tumor
cell response to tamoxifen therapy. Accordingly, IPA ana-
lysis identified miR-342 regulated genes significantly
represented in multiple pathways that directly regulate
breast tumor cell cycle progression including cyclin B1,
p53, and BRCA1. Taken together our results provide a
genomic basis to explore the role of miR-342 regulated
genes in multiple tamoxifen actions including both apop-
tosis and cytostasis.
Conclusions
In summary, we have identified miR-342 as an important
mediator of tamoxifen response in both breast tumor cell
lines and breast cancer patients. Our results suggest that
miR-342 expression and/or expression of the surrogate
marker EVL may emerge as important breast tumor mar-
kers predicting clinical response to tamoxifen interven-
tion. With the potential of miRNA therapy, restoring
miR-342 expression may constitute a novel therapeutic
strategy to sensitize endocrine refractory breast tumors.
Additional material
Additional file 1: Levels of miR-342-3p and miR-342-5p expression
in breast tumor cell lines. File shows qRT-PCR data comparing levels of
miR-342-3p and miR-342-5p expression in experimental cell lines. Total
RNA was isolated from each cell line and miR-342-3p or miR-342-5p
expression levels relative to GAPDH were analyzed by qRT-PCR. Data is
represented as mean +/- SE of three independent RNA extractions.
Additional file 2: Scoring of miR-342 expression by ISH in primary
breast tumors and breast tumor cell lines. File contains controls for
ISH showing different levels of miR-342 expression and ISH scoring. (A-D)
ISH for miR-342 expression was performed and scored on each primary
breast tumor as described in the materials and methods. The samples
are scored as (A) 0, (B) 1, (C) 2, and (D) 3. (E) Total RNA was isolated from
each cell line and miR-342 expression levels analyzed by qRT-PCR were
normalized to RNU44. Data relative to untreated MCF-7/HER2Δ16 is
represented as mean +/- SE of three independent RNA extractions. (F)
Mir-342 ISH was performed on each formalin fixed and paraffin
embedded cell line. Indicated fold changes in miR-342 expression were
obtained from the qRT-PCR from E.
Additional file 3: Levels of miR-342-3p and miR-342-5p expression
in MCF-7/HER2Δ16 cell lines. File shows qRT-PCR data comparing levels
of miR-342-3p and miR-342-5p expression in MCF-7/HER2Δ16 stable cell
lines. Total RNA was isolated from each cell line and miR-342-3p or miR-
342-5p expression levels relative to RNU44 were analyzed by qRT-PCR.
Data is represented as mean +/- SE of three independent RNA
extractions. Levels of miR-342-5p expression were at the lower limits of
qRT-PCR sensitivity.
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